Exelixis
EXEL
#1653
Rank
NZ$22.81 B
Marketcap
NZ$92.06
Share price
-1.47%
Change (1 day)
43.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$5.35

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$5.29. In 2025 the company made an earnings per share (EPS) of NZ$4.89.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$5.359.57%
2025NZ$4.89
2023NZ$1.1014.61%
2022NZ$0.96-22.97%
2021NZ$1.25100%
2020NZ$0.63-65.09%
2019NZ$1.79-53.91%
2018NZ$3.89333.96%
2017NZ$0.90-260.61%
2016NZ-$0.56-58.75%
2015NZ-$1.35-42.45%
2014NZ-$2.355.3%
2013NZ-$2.23

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$14.77 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.21-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.48 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.33-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$6.04 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.02 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.57 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$40.24-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.42-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA